Literature DB >> 6099388

Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall.

H Okunishi, M Miyazaki, N Toda.   

Abstract

An inhibitor of angiotensin I (ANG I) converting enzyme, SA446, reduced the response to ANG I of blood vessels isolated from dogs and monkeys, but did not abolish the response even at high concentrations. The residual action of ANG I in the presence of high concentrations of SA446 could be abolished by (Sar1, Ala8)-ANG II. Vascular strips and crude extracts of vessels and lungs possessed the enzymic activity generating ANG II from ANG I, or hippuric acid from hippuryl-histidyl-leucine (HHL). The HHL-hydrolysing activity of the crude extracts was completely inhibited by SA446 (10(-7) mol/l) and/or Na2-EDTA (10(-3) mol/l). However, the octapeptide generation was not abolished despite the combined treatment with SA446 (5 X 10(-4) mol/l) and Na2-EDTA (5 x 10(-3) mol/l). The residual activity forming ANG II was inhibited by chymostatin and soybean trypsin inhibitor, which however did not affect the HHL-hydrolysis. Combined treatment with SA446 (10(-5) mol/l) and chymostatin (2.5 X 10(-5) mol/l) abolished the vascular action of ANG I but did not alter the action of ANG II. These results strongly suggest that besides the ANG I converting enzyme, another enzyme which generates ANG II is present in vascular tissues and lungs, and may play an important role in the local generation of ANG II, which possibly regulates the regional vascular tone.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6099388

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  15 in total

1.  Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? AT1-receptor antagonists?

Authors:  Uta C Hoppe
Journal:  Clin Res Cardiol       Date:  2007-02-15       Impact factor: 5.460

Review 2.  Circulating and tissue angiotensin systems.

Authors:  D J Campbell
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

3.  Increased catecholamine secretion contributes to hypertension in TRPM4-deficient mice.

Authors:  Ilka Mathar; Rudi Vennekens; Marcel Meissner; Frieder Kees; Gerry Van der Mieren; Juan E Camacho Londoño; Sebastian Uhl; Thomas Voets; Björn Hummel; An van den Bergh; Paul Herijgers; Bernd Nilius; Veit Flockerzi; Frank Schweda; Marc Freichel
Journal:  J Clin Invest       Date:  2010-08-02       Impact factor: 14.808

4.  A novel vascular smooth muscle chymase is upregulated in hypertensive rats.

Authors:  C Guo; H Ju; D Leung; H Massaeli; M Shi; M Rabinovitch
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

5.  Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart.

Authors:  H Urata; K D Boehm; A Philip; A Kinoshita; J Gabrovsek; F M Bumpus; A Husain
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

6.  Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon.

Authors:  B D Hoit; Y Shao; A Kinoshita; M Gabel; A Husain; R A Walsh
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 7.  RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.

Authors:  Christian Werner; Magnus Baumhäkel; Koon K Teo; Roland Schmieder; Johannes Mann; Thomas Unger; Salim Yusuf; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2008-05-03       Impact factor: 5.460

Review 8.  Stimulation of endothelial progenitor cells: a new putative effect of several cardiovascular drugs.

Authors:  Natália António; Rosa Fernandes; Noela Rodriguez-Losada; Manuel F Jiménez-Navarro; Artur Paiva; Eduardo de Teresa Galván; Lino Gonçalves; Carlos Fontes Ribeiro; Luís A Providência
Journal:  Eur J Clin Pharmacol       Date:  2009-12-10       Impact factor: 2.953

9.  Involvement of chymase-mediated angiotensin II generation in blood pressure regulation.

Authors:  Ming Li; Ke Liu; Jan Michalicek; James A Angus; John E Hunt; Louis J Dell'Italia; Michael P Feneley; Robert M Graham; Ahsan Husain
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

Review 10.  Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial.

Authors:  B Pitt; P Chang; P B Timmermans
Journal:  Cardiovasc Drugs Ther       Date:  1995-10       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.